William G. Wierda, MD, PhD, on Evolving Strategies for First-Line Treatment of CLL
NCCN 2019 Annual Congress: Hematologic MalignanciesWilliam G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, offers commentary on the debate about evolving strategies in first-line chronic lymphocytic leukemia, the clinical trials on such agents as ibrutinib, BTK inhibitors, and venetoclax, and the interest in chemoimmunotherapy as a fixed duration treatment.